How to stop hair loss from GLP-1 female
You are dealing with a symptom and want to know if it is expected.
Reference and calculator, not medical advice. This page explains how something works; it does not tell you what to take. Last reviewed August 2026.
If you are a woman and you noticed this, the labels confirm you are not imagining a pattern. In every trial that broke the figures down by sex, hair loss was reported several times more often in women than in men — and the gap is far larger than the gap between doses.
The clearest number in any of the labels
Wegovy trials, women only, same measurement across three arms. Rate rises with dose while the label attributes the effect to weight reduction rather than to the drug.
Men in the same trials: 0% · 0% · 0.2%. The sex difference is larger than the dose difference, which is the part almost no summary of this topic mentions.
Why the women’s figure for 2.4 mg differs from the table above: these three arms come from the 7.2 mg trial programme, while the other figure is pooled from three earlier weight-management trials. Both are in the label and both report 3.3% overall at 2.4 mg — the sex split differs because the trial populations do. Both are shown rather than picking the more striking one.
In the Wegovy 7.2 mg trials the rate was 8.4% in women and 0.2% in men. On Zepbound, 7.1% of women and 0.5% of men. The placebo groups show the same skew at a lower level — 2% of women and none of the men on placebo in the Wegovy pool, 1.3% versus 0% on Zepbound. Whatever is happening is happening much more to women, and it was already happening at a lower rate to women who were not on the drug at all.
What each label actually reports
Incidence figures come from the adverse-reaction sections of the prescribing information. The two weight-management products report trial data; the diabetes products list alopecia only as a postmarketing report.
| Product | Reported in | Women | Men |
|---|---|---|---|
| Wegovy Semaglutide | Clinical trials | 4% | 0.9% |
| Zepbound Tirzepatide | Clinical trials | 7.1% | 0.5% |
| Ozempic Semaglutide | Postmarketing reports only | no denominator | no denominator |
| Mounjaro Tirzepatide | Postmarketing reports only | no denominator | no denominator |
| Rybelsus Semaglutide (oral) | Postmarketing reports only | no denominator | no denominator |
| Saxenda Liraglutide | Postmarketing reports only | no denominator | no denominator |
| Trulicity Dulaglutide | Postmarketing reports only | no denominator | no denominator |
A postmarketing entry means the reaction has been reported after approval but the label gives no rate, because spontaneous reports have no denominator. It is not evidence that the rate is lower — only that it was not measured. Every figure above is checked against the label linked at the foot of this page.
On stopping it: no label offers a treatment, a prevention strategy, or a duration. That absence is not an oversight you can route around by searching harder — it means the studies that would support such a claim have not been done for this population. What the labels do give you is leverage in a conversation with your prescriber, because you can point at a documented, sex-skewed, dose-related reaction rather than describing a feeling.
Common questions
- Is there anything shown to prevent it?
- Nothing in any of the seven labels. No supplement, vitamin, shampoo or topical is named as preventing or treating this reaction, because none has been tested against it in these trials. Products marketed for it are making a claim the source documents do not support.
- Would a lower dose help?
- The reported rate is lower at lower doses — 3.3% at Wegovy 2.4 mg versus 5.8% at 7.2 mg. Whether changing your dose is appropriate is entirely a prescriber decision, and it trades against why you are taking it in the first place.
- Why women so much more than men?
- The labels report the difference and offer no explanation for it. This site will not invent one. It is a genuinely open question in the source material.
- What should I actually ask my prescriber?
- Whether anything unrelated could be contributing — thyroid function, iron status, and other medications all affect hair and are checkable. The trial data cannot tell you whether your shedding is the reaction described in the label or something else entirely, and that distinction changes what to do.
Sources and last review
This page is general reference rather than a dosing table, so it quotes no figures from a label. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- This page carries no product-specific dosing figures. The labels behind everything on this site are listed on the sources page, and the originals live on DailyMed.
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Citing this page
The figures here are transcribed from FDA-approved labels and each links to its source. If you are writing about this, quote the label rather than this site where you can — and if this page saved you the transcription, a link is appreciated.
Gavin. "How to stop hair loss from GLP-1 female." GLP1Meter, reviewed August 2026. https://glp1meter.com/side-effects/how-to-stop-hair-loss-from-glp-1-female/<a href="https://glp1meter.com/side-effects/how-to-stop-hair-loss-from-glp-1-female/">How to stop hair loss from GLP-1 female</a> — GLP1Meter, reviewed August 2026Gavin. (2026). How to stop hair loss from GLP-1 female. GLP1Meter. Retrieved from https://glp1meter.com/side-effects/how-to-stop-hair-loss-from-glp-1-female/
Also searched as: how to stop hair loss from glp 1 female